search
Back to results

A Phase II MULTICENTRE Trial of Needle Based Laser Confocal Endomicroscopy of Cystic and Solid Tumours of the Pancreas (CONCYST)

Primary Purpose

Pancreatic Cyst, Serous Cystadenoma, Intraductal Papillary Mucinous Neoplasm

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
AQ-Flex 19 probe (Mauna Kea Technologies, Paris)
Sponsored by
University College, London
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Pancreatic Cyst

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. A diagnosis of a pancreatic cystic tumour based on multidisciplinary review of imaging for which EUS-FNA is indicated.
  2. Pancreatic cystic tumour >1cm in size.
  3. ECOG performance status 0, 1 or 2.
  4. Estimated life expectancy of at least 12 weeks.
  5. Age >18 years.
  6. Capable of giving written informed consent.
  7. Has not has pancreatitis within the previous 3 months.
  8. Women of child-bearing potential must have a negative pregnancy test in the week before nCLE, AND be using an adequate contraception method, which must be continued for at least 1 week after nCLE.

Exclusion Criteria:

  1. Acute pancreatitis in the last 3 months.
  2. Subject with multiple cysts
  3. Subjects for whom EUS-FNA or surgery are contraindicated
  4. Known allergy to fluorescein dye
  5. Any evidence of severe or uncontrolled systemic diseases or laboratory finding that in the view of the investigator makes it undesirable for the patient to participate in the trial.
  6. Any psychiatric disorder making reliable informed consent impossible.
  7. Pregnancy or breast-feeding.
  8. ECOG performance status 3 or 4

Sites / Locations

  • Addenbrookes Hospital
  • Royal Free Hospital
  • University College London Hospitals
  • Freeman Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

EUS guided nCLE

Arm Description

For patients with indeterminate cystic lesions of the pancreas, in addition to routine diagnostic investigations, patients participating in the study will undergo needle based confocal laser endomicroscopy (using the AQ-flex 19 probe - Mauna Kea Technologies, Paris France) at the time of their endoscopic ultrasound.

Outcomes

Primary Outcome Measures

Diagnostic accuracy
Assess the diagnostic accuracy of the Cellvizio nCLE system for diagnosing cystic lesions of the pancreas, compared to standard diagnostic modalities

Secondary Outcome Measures

Adverse events
Record the number of participants with an adverse event due to EUS-nCLE
Interpretation criteria
Develop and validate interpretation criteria for nCLE in the pancreas
Assess margins
Assess the diagnostic accuracy of nCLE in defining the margins and extent of pancreatic tumours intraoperatively

Full Information

First Posted
June 22, 2015
Last Updated
September 30, 2019
Sponsor
University College, London
Collaborators
Cambridge University Hospitals NHS Foundation Trust
search

1. Study Identification

Unique Protocol Identification Number
NCT02523170
Brief Title
A Phase II MULTICENTRE Trial of Needle Based Laser Confocal Endomicroscopy of Cystic and Solid Tumours of the Pancreas
Acronym
CONCYST
Official Title
A Phase II MULTICENTRE Trial of Needle Based Laser Confocal Endomicroscopy of Cystic and Solid Tumours of the Pancreas
Study Type
Interventional

2. Study Status

Record Verification Date
September 2019
Overall Recruitment Status
Completed
Study Start Date
July 2014 (Actual)
Primary Completion Date
October 2016 (Actual)
Study Completion Date
April 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University College, London
Collaborators
Cambridge University Hospitals NHS Foundation Trust

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
A multicentre phase II study to determine the safety and efficacy of EUS-guided nCLE in patients with suspected cystic tumours of the pancreas in whom endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) is clinically indicated. Patients will be recruited sequentially to undergo nCLE as part of their routine diagnostic evaluation, followed by standard surveillance. This part of the study will recruit 60 patients.
Detailed Description
A multicentre phase II study to determine the safety and efficacy of EUS-guided nCLE in patients with suspected cystic tumours of the pancreas in whom endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) is clinically indicated. Patients will be recruited sequentially to undergo nCLE as part of their routine diagnostic evaluation, followed by standard surveillance. This part of the study will recruit 60 patients. The study also includes a feasibility study to evaluate the role of intraoperative nCLE in the diagnosis and staging of pancreatic tumours. This part of the study will recruit a further 20 patients. Primary endpoint: Assess the diagnostic performance of the Cellvizio nCLE system in the characterization of pancreatic cysts, compared to standard diagnostic modalities. Secondary endpoints: Assess the safety and efficacy of EUS-nCLE. Assess the impact of the Cellvizio nCLE system on the management of patients with pancreatic cysts. Develop and validate interpretation criteria for nCLE in the pancreas. Assess the diagnostic performance of nCLE in characterising and staging pancreatic tumours intraoperatively.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pancreatic Cyst, Serous Cystadenoma, Intraductal Papillary Mucinous Neoplasm, Cystadenoma, Mucinous

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
67 (Actual)

8. Arms, Groups, and Interventions

Arm Title
EUS guided nCLE
Arm Type
Experimental
Arm Description
For patients with indeterminate cystic lesions of the pancreas, in addition to routine diagnostic investigations, patients participating in the study will undergo needle based confocal laser endomicroscopy (using the AQ-flex 19 probe - Mauna Kea Technologies, Paris France) at the time of their endoscopic ultrasound.
Intervention Type
Device
Intervention Name(s)
AQ-Flex 19 probe (Mauna Kea Technologies, Paris)
Intervention Description
Needle-based Confocal Laser Endomicroscopy (nCLE)
Primary Outcome Measure Information:
Title
Diagnostic accuracy
Description
Assess the diagnostic accuracy of the Cellvizio nCLE system for diagnosing cystic lesions of the pancreas, compared to standard diagnostic modalities
Time Frame
3 years
Secondary Outcome Measure Information:
Title
Adverse events
Description
Record the number of participants with an adverse event due to EUS-nCLE
Time Frame
3 years
Title
Interpretation criteria
Description
Develop and validate interpretation criteria for nCLE in the pancreas
Time Frame
3 years
Title
Assess margins
Description
Assess the diagnostic accuracy of nCLE in defining the margins and extent of pancreatic tumours intraoperatively
Time Frame
3 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: A diagnosis of a pancreatic cystic tumour based on multidisciplinary review of imaging for which EUS-FNA is indicated. Pancreatic cystic tumour >1cm in size. ECOG performance status 0, 1 or 2. Estimated life expectancy of at least 12 weeks. Age >18 years. Capable of giving written informed consent. Has not has pancreatitis within the previous 3 months. Women of child-bearing potential must have a negative pregnancy test in the week before nCLE, AND be using an adequate contraception method, which must be continued for at least 1 week after nCLE. Exclusion Criteria: Acute pancreatitis in the last 3 months. Subject with multiple cysts Subjects for whom EUS-FNA or surgery are contraindicated Known allergy to fluorescein dye Any evidence of severe or uncontrolled systemic diseases or laboratory finding that in the view of the investigator makes it undesirable for the patient to participate in the trial. Any psychiatric disorder making reliable informed consent impossible. Pregnancy or breast-feeding. ECOG performance status 3 or 4
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Steve Pereira, PhD FRCP
Organizational Affiliation
University College, London
Official's Role
Principal Investigator
Facility Information:
Facility Name
Addenbrookes Hospital
City
Cambridge
Country
United Kingdom
Facility Name
Royal Free Hospital
City
London
Country
United Kingdom
Facility Name
University College London Hospitals
City
London
Country
United Kingdom
Facility Name
Freeman Hospital
City
Newcastle
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
31475228
Citation
Keane MG, Wehnert N, Perez-Machado M, Fusai GK, Thorburn D, Oppong KW, Carroll N, Metz AJ, Pereira SP. A prospective trial of CONfocal endomicroscopy in CYSTic lesions of the pancreas: CONCYST-01. Endosc Int Open. 2019 Sep;7(9):E1117-E1122. doi: 10.1055/a-0957-2976. Epub 2019 Aug 29.
Results Reference
background
Links:
URL
https://www.ncbi.nlm.nih.gov/pubmed/31475228
Description
Publication

Learn more about this trial

A Phase II MULTICENTRE Trial of Needle Based Laser Confocal Endomicroscopy of Cystic and Solid Tumours of the Pancreas

We'll reach out to this number within 24 hrs